{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:24:10Z","timestamp":1793139850221,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Left ventricular (LV) hypertrophy (LVH) in patients with hypertension is a significant risk factor for cardiovascular mortality and morbidity. However, the prognostic implication of LVH regression after antihypertensive therapy has not been clearly investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who underwent echocardiography at the time of the diagnosis of hypertension and repeated echocardiography at an interval of 6\u201318 months were retrospectively identified. LVH was defined as LV mass index (LVMI) &amp;gt;115 g\/m<jats:sup>2<\/jats:sup> (men) and &amp;gt;95 g\/m<jats:sup>2<\/jats:sup> (women). LVH regression was defined as LVH at initial echocardiography with normal geometry or concentric LV remodeling at follow-up echocardiography. Cardiovascular mortality, hospitalization for heart failure (HHF), coronary revascularization, stroke, and aortic events were analyzed according to changes in LVMI and geometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1,872 patients, 44.7% (<jats:italic>n<\/jats:italic> = 837) had LVH at the time of diagnosis; among these, 30.7% showed LVH regression. The reduction in LVMI was associated with the reduction in BP, especially in those with LVH at baseline. During follow up (median, 50.4 months; interquartile range, 24.9\u2013103.2 months), 68 patients died of cardiovascular causes, 127 had HHF, and 162 had vascular events (coronary revascularization, stroke, and aortic events). Persistent or newly developed LVH during antihypertensive therapy was a significant predictor of cardiovascular mortality and events, especially HHF. On multivariable analysis, women, diabetes, atrial fibrillation, coronary artery disease, larger LVMI and end-diastolic dimension, and less reduction in systolic BP were associated with persistent or newly developed LVH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LVH regression in patients with hypertension is associated with a reduction in cardiovascular events and can be used as a prognostic marker.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1082008","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T05:21:40Z","timestamp":1671513700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension"],"prefix":"10.3389","volume":"9","author":[{"given":"Hyue Mee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Chang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonyee Elizabeth","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goo-Yeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5494\/wjh.v5.i2.41","article-title":"Hypertensive cardiomyopathy: a clinical approach and literature review.","volume":"55","author":"Kuroda","year":"2015","journal-title":"World J Hypertens."},{"key":"B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1291\/hypres.28.191","article-title":"Hypertensive heart disease.","volume":"28","author":"Diamond","year":"2005","journal-title":"Hypertens Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1885-5857(06)60781-0","article-title":"[Hypertensive heart disease: a proposed clinical classification].","volume":"59","author":"Alegr\u00eda-Ezquerra","year":"2006","journal-title":"Rev Esp Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.numecd.2008.12.012","article-title":"Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study.","volume":"19","author":"de Simone","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/HYPERTENSIONAHA.107.107474","article-title":"Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.","volume":"51","author":"Gerdts","year":"2008","journal-title":"Hypertension."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000144","article-title":"Lack of reduction of left ventricular mass in treated hypertension: the strong heart study.","volume":"2","author":"de Simone","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.7326\/0003-4819-114-5-345","article-title":"Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.","volume":"114","author":"Koren","year":"1991","journal-title":"Ann Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.7326\/0003-4819-117-10-831","article-title":"The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease.","volume":"117","author":"Ghali","year":"1992","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1161\/hc4201.097944","article-title":"Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.","volume":"104","author":"Verdecchia","year":"2001","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ajh.2008.2","article-title":"Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.","volume":"21","author":"Pierdomenico","year":"2008","journal-title":"Am J Hypertens."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies.","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension."},{"key":"B14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/ajh.2010.80","article-title":"Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis.","volume":"23","author":"Pierdomenico","year":"2010","journal-title":"Am J Hypertens."},{"key":"B15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0895-7061(03)01018-5","article-title":"Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis.","volume":"16","author":"Verdecchia","year":"2003","journal-title":"Am J Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0895-7061(02)03061-3","article-title":"Left ventricular mass change during treatment and outcome in patients with essential hypertension.","volume":"15","author":"Koren","year":"2002","journal-title":"Am J Hypertens."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/00004872-199510000-00003","article-title":"Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.","volume":"13","author":"Muiesan","year":"1995","journal-title":"J Hypertens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment of hypertension.","volume":"292","author":"Devereux","year":"2004","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.ijcard.2012.06.084","article-title":"Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients.","volume":"167","author":"Costanzo","year":"2013","journal-title":"Int J Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/HYPERTENSIONAHA.119.13073","article-title":"Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the SPRINT-HEART.","volume":"74","author":"Upadhya","year":"2019","journal-title":"Hypertension."},{"key":"B21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/HYPERTENSIONAHA.115.06731","article-title":"Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications.","volume":"67","author":"Kim","year":"2016","journal-title":"Hypertension."},{"key":"B22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijcard.2007.04.114","article-title":"Antihypertensive drug medication adherence and its affecting factors in South Korea.","volume":"128","author":"Park","year":"2008","journal-title":"Int J Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.echo.2015.05.002","article-title":"Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE).","volume":"28","author":"Marwick","year":"2015","journal-title":"J Am Soc Echocardiogr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7326\/0003-4819-108-1-7","article-title":"Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study.","volume":"108","author":"Levy","year":"1988","journal-title":"Ann Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/jhh.2011.104","article-title":"Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies.","volume":"26","author":"Cuspidi","year":"2012","journal-title":"J Hum Hypertens."},{"key":"B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease.","volume":"123","author":"Drazner","year":"2011","journal-title":"Circulation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update.","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004152","article-title":"Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network).","volume":"6","author":"Lonnebakken","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.numecd.2018.10.010","article-title":"Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: the Campania Salute Network.","volume":"29","author":"Lonnebakken","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","article-title":"Myocardial remodeling in hypertension.","volume":"72","author":"Gonzalez","year":"2018","journal-title":"Hypertension."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines.","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1082008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T05:21:45Z","timestamp":1671513705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1082008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":35,"alternative-id":["10.3389\/fcvm.2022.1082008"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1082008","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"article-number":"1082008"}}